The FEV1 is widely used by physicians in the diagnosis, staging, treatment, monitoring and
establishing prognosis for patients with COPD. The MCID is the smallest difference which …

Inhalation of drug aerosols is a modern pathway to combat lung diseases. It is also
becoming the preferred route for insulin delivery, pain management, cancer therapy, and …

Investigation has repeatedly demonstrated an association between exposure to ambient air
pollution particles and numerous indices of human morbidity and mortality. Individuals with …

Background Tiotropium, a once-daily anticholinergic, and salmeterol represent two inhaled,
long-acting bronchodilators from different pharmacologic classes. A trial was designed to …

Rationale: Evidence suggests that tumor necrosis factor (TNF)-α plays an important role in
the pathophysiology of sarcoidosis. Objectives: To assess the efficacy of infliximab in …

Study objectives To examine and compare the efficacy and safety of salmeterol xinafoate, a
long-acting inhaledβ 2-adrenergic agonist, with inhaled ipratropium bromide and inhaled …

Rationale: Indacaterol is the first once-daily, long-acting inhaled β2-agonist bronchodilator
studied in patients with chronic obstructive pulmonary disease (COPD). Objectives: To …

Rationale: Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-
related, inflammatory lung disease in which tumor necrosis factor-α is overexpressed and …

Simulation results of microparticle and nanoparticle deposition patterns, local
concentrations, and segmental averages are contrasted for a human upper airway model …

Study objective To examine the efficacy and safety of the once-daily, inhaled, long-acting
muscarinic antagonist/β 2-agonist combination umeclidinium/vilanterol (UMEC/VI) …